Latest From Teijin Ltd.
Roche’s neuroscience strategy of following the science, taking on lessons from open label extensions from Phase III studies, is vital to the success of gantenerumab, the company said in an interview with Scrip.
Mesenchymal stem cell-based therapy's missed Phase IIb endpoint in stroke prompts both an assessment of future development plans and a precipitous fall in developers' stocks.
Another expected knockback by the European Medicines Agency's scientific committee is expected for Radius' lead product after the company revealed a negative trend vote for the osteoporosis therapy.
The drug has become the only neurotoxin to be approved for excessive drooling in the US, giving Merz an advantage over rivals such as Allergan's Botox to treat a condition that affects over 600,000 adults across the Atlantic.
- Therapeutic Areas
- Pacific Rim
- Company Type
- Top Japanese Pharma
- Parent & Subsidiaries
- Teijin Ltd.
- Senior Management
- Jun Suzuki, Pres. & CEO
- Contact Info
Phone: (81) 3 3506 4529
2-1, Kasumigaseki 3-chome
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.